Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
HIV, hepatitus B, flu, tuberculosis, COVID-19: these deadly infectious diseases persist because they overwhelm the human immune system, and because previous treatments have failed to target their vulnerabilities. Vir is counterattacking on multiple fronts. It engineers new antibodies to neutralize pathogens, uses viral vectors to reprogram T cells to be more potent, finds ways to boost the innate immune system, and uses small interfering RNA molecules to suppress viral replication. Vir Biotechnology acquired Agenovir in 2018.
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules